Agenda: Ontario Steering Committee for Cancer Drugs (OSCCD)

Date: June 19, 2023 Time: 1:00-3:00PM Microsoft Teams meeting

cancer

Closing remarks

o Housekeeping Items

2:20-2:55

2:55-3:00

Trastuzumab emtansine (T-DM1) for early breast

Time	Topic	Description	Presenter(s)
1:00-1:05	WelcomeAgenda and ObjectivesConflict of Interest (COI) Declarations	Inform members	Interim Chair
1:05-1:40	Lenalidomide with bortezomib/dexamethasone (RVd) for transplant-eligible multiple myeloma	Request for Advice [non-voting item]	Clinical Presenter Budget Impact Analysis (BIA) Presenter
1:40-2:15	Encorafenib with panitumumab (or cetuximab) for small bowel and appendiceal cancers	Request for Advice [non-voting item]	Clinical Presenter BIA Presenter
			Alternate committee member will be acting Interim Chair for this item
		5-Minute Break	

Request for Advice

[non-voting item]

Inform members

Clinical Presenter

BIA Presenter

Interim Chair